- Home
- KOD vs NBTX Comparison
KOD vs NBTX Comparison
Compare KOD & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- NBTX
- Stock Information
- Founded
- KOD 2009
- NBTX 2003
- Country
- KOD United States
- NBTX France
- Employees
- KOD N/A
- NBTX N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- KOD Health Care
- NBTX Health Care
- Exchange
- KOD Nasdaq
- NBTX Nasdaq
- Market Cap
- KOD 198.4M
- NBTX 211.9M
- IPO Year
- KOD 2018
- NBTX 2020
- Fundamental
- Price
- KOD $9.35
- NBTX $9.32
- Analyst Decision
- KOD Hold
- NBTX Strong Buy
- Analyst Count
- KOD 4
- NBTX 1
- Target Price
- KOD $11.75
- NBTX $8.00
- AVG Volume (30 Days)
- KOD 556.4K
- NBTX 14.8K
- Earning Date
- KOD 11-13-2025
- NBTX 09-18-2025
- Dividend Yield
- KOD N/A
- NBTX N/A
- EPS Growth
- KOD N/A
- NBTX N/A
- EPS
- KOD N/A
- NBTX N/A
- Revenue
- KOD N/A
- NBTX N/A
- Revenue This Year
- KOD N/A
- NBTX N/A
- Revenue Next Year
- KOD N/A
- NBTX $74.67
- P/E Ratio
- KOD N/A
- NBTX N/A
- Revenue Growth
- KOD N/A
- NBTX N/A
- 52 Week Low
- KOD $1.92
- NBTX $2.76
- 52 Week High
- KOD $11.60
- NBTX $10.59
- Technical
- Relative Strength Index (RSI)
- KOD 52.81
- NBTX 58.14
- Support Level
- KOD $8.91
- NBTX $8.03
- Resistance Level
- KOD $10.20
- NBTX $10.46
- Average True Range (ATR)
- KOD 0.75
- NBTX 0.55
- MACD
- KOD -0.12
- NBTX -0.04
- Stochastic Oscillator
- KOD 45.49
- NBTX 53.08
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.